July 9-14, 2017
São Paulo, Brazil
Charles Mowbray, Head of Discovery, DNDi presented on drug discovery for neglected diseases.
June 18-20, 2017
GlaxoSmithKline, Tres Cantos, Madrid, Spain
Ben Perry, NTD Drug Discovery Booster Project Manager, and Charles Mowbray, Head of Discovery, presented on the NTD Discovery Booster, aminopyrazoles and NTDs..
Diagnostics, drug discovery and development
May 16-17, 2017
London, United Kingdom
Ivan Scandale, Project Manager, DNDi, presented on drug development approaches for filarial diseases.
April 19-22, 2017
Bernard Pécoul, Executive Director, and Wilfried Mutombo HAT Project Coordinator at DNDi, spoke at the event.
April 2-5, 2017
Charles Mowbray, Head of Drug Discovery at DNDi presented on catalyzing R&D for neglected diseases.
February 27 – March 1, 2017
Suman Rijal, Director of the DNDi Regional Office in India, presented at the event.
International Society for Neglected Tropical Diseases Festival
February 23, 2017
London, United Kingdom
James Arkinstall, DNDi‘s Head of Communications & Advocacy, presented on the fundraising campaign for sleeping sickness with the Huffington Post.
KEMRI Annual Scientific and Health Conference
February 8-10, 2017
Gina Ouattara, Project Coordinator for HIV/HCV, and Kevin Onyango, Project Coordinator for Mycetoma, both from the DNDi Africa office, presented at the event.
Assessing the health of vulnerable population for an inclusive society
January 29-February 3, 2017
Marc Lallemant, Head of Paediatric HIV Program at DNDi spoke at the event and Jean-Michel Piedagnel, Head of DNDi South East-Asia Regional Office hosted a Q&A session.
Our staff, partners, and stakeholders share their highlights from 2016.
Ärzteblatt [1 December, 2016]
“Mehr Geld für die Forschung zu armutsbedingten Erkrankungen” – “More money for research on poverty-related diseases”
WuXi App Tec [1 December, 2016]
“Harnessing science for the most neglected diseases – A chat with Charles Mowbray, Ph.D., Head of Drug Discovery, DNDi“
KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi
DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.
Lab Bulletin [15 November, 2016]
“Newly discovered protein may hold key to better drugs for neglected diseases”
La Depeche [7 November, 2016]
“La loase, une parasitose pas bénigne” – “Loa Loa parasites are not benign”
by Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rägo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, ’t Hoen EFM, Wagner AK, Yadav P, Reich MR.
The Lancet, November 2016
ABC [1 November, 2016]
“Toda España, salvo la cornisa cantábrica, es endémica de leishmaniasis?” – “All Spain, except for the Cantabrian coast, leishmaniasis is endemic”
Health Canal [28 October, 2016]
“African Eye Worm is worse than it looks: new study shows that the disease leads to increased mortality”
[Geneva, Switzerland – October 22, 2016]
Potentially refutes assumption that Loa Loa is a benign disease and highlights R&D gap for filarial diseases
A filarial worm infection called Loiasis that affects over 10 million people in Africa and has been assumed to be a relatively harmless disease could possibly contribute to increased risk of death, according to a study recently published in Lancet Infectious Diseases.